Amendment to Schedule 13D for Cocrystal Pharma, Inc. by Phillip Frost, M.D. and Frost Gamma Investments Trust

This filing is an amendment to Schedule 13D for Cocrystal Pharma, Inc., submitted by Phillip Frost, M.D. and Frost Gamma Investments Trust. The amendment reports the acquisition of shares of common stock through the vesting of restricted stock units. Dr. Frost acquired 13,550 shares on August 21, 2025, and 1,693 shares on September 30, 2025. The shares are held by Frost Gamma Investments Trust, of which Dr. Frost is the trustee. Dr. Frost disclaims beneficial ownership of these shares except to the extent of any pecuniary interest. The filing also details the ownership structure, indicating that Dr. Frost is the beneficial owner of 1,382,873 shares, representing 10.6% of the outstanding shares. The purpose of the acquisition is for investment purposes.